Theravance Biopharma Inc TBPH shares are trading lower in Monday's after-hours session after the company announced the results from Study 0170 showed the primary endpoint was not statistically significant for the overall population of patients.
The overall population included patients with Parkinson's disease, pure autonomic failure and multiple system atrophy. The odds ratio suggests that patients receiving ampreloxetine had a 40% reduction in the odds of treatment failure compared to placebo.
Theravance Biopharma is a diversified biopharmaceutical company focused on the discovery, development and commercialization of organ-selective medicines.
See Also: Why Carnival Shares Are Cruising Higher After Hours
TBPH 52-Week Range: $6.10 - $22.74
The stock was down 3.47% in after hours at $9.17 at time of publication, according to data from Benzinga Pro.
Photo: AhmadArdity from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
